Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels
Tóm tắt
Từ khóa
Tài liệu tham khảo
Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001
Reiner, 2011, ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158
Bader, 2010, Liver tests are irrelevant when prescribing statins, Lancet, 376, 1882, 10.1016/S0140-6736(10)62142-3
Cohen, 2006, An assessment of statin safety by hepatologists, Am J Cardiol, 97, 77C, 10.1016/j.amjcard.2005.12.014
Kotronen, 2007, Liver fat in the metabolic syndrome, J Clin Endocrinol Metab, 92, 3490, 10.1210/jc.2007-0482
Kotronen, 2008, Fatty liver: a novel component of the metabolic syndrome, Arterioscler Thromb Vasc Biol, 28, 27, 10.1161/ATVBAHA.107.147538
Westerbacka, 2004, Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk, Diabetologia, 47, 1360, 10.1007/s00125-004-1460-1
Miyake, 2012, Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study, J Gastroenterol, 47, 696, 10.1007/s00535-012-0534-y
Simental-Mendia, 2012, The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 24, 1173, 10.1097/MEG.0b013e3283564ee5
Neuschwander-Tetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference, Hepatology, 37, 1202, 10.1053/jhep.2003.50193
Vanni, 2010, From the metabolic syndrome to NAFLD or vice versa?, Dig Liver Dis, 42, 320, 10.1016/j.dld.2010.01.016
Schindhelm, 2007, Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study, Atherosclerosis, 191, 391, 10.1016/j.atherosclerosis.2006.04.006
Meisinger, 2006, Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population, Atherosclerosis, 189, 297, 10.1016/j.atherosclerosis.2006.01.010
Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787
Athyros, 2010, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis, Lancet, 376, 1916, 10.1016/S0140-6736(10)61272-X
Pedersen, 2004, Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study, Am J Cardiol, 94, 720, 10.1016/j.amjcard.2004.06.003
Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437
Hansson, 1992, Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials, Blood Press, 1, 113, 10.3109/08037059209077502
Deedwania, 2006, Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study, Lancet, 368, 919, 10.1016/S0140-6736(06)69292-1
Waters, 2004, Treating to New Targets study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental benefit?, Am J Cardiol, 93, 154, 10.1016/j.amjcard.2003.09.031
Ballantyne, 2001, Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S, Circulation, 104, 3046, 10.1161/hc5001.100624
Miettinen, 1990, Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population, Am J Epidemiol, 131, 20, 10.1093/oxfordjournals.aje.a115479
Simonen, 2011, Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity, J Hepatol, 54, 153, 10.1016/j.jhep.2010.05.037
Puri, 2007, A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, 46, 1081, 10.1002/hep.21763
Yao, 2000, Free cholesterol loading of macrophages induces apoptosis involving the fas pathway, J Biol Chem, 275, 23807, 10.1074/jbc.M002087200
Austin, 1999, Low-density lipoprotein subclass phenotypes, triglycerides and coronary heart disease, 611